CN104093405A - 用于治疗癌症的治疗组合 - Google Patents

用于治疗癌症的治疗组合 Download PDF

Info

Publication number
CN104093405A
CN104093405A CN201280051254.5A CN201280051254A CN104093405A CN 104093405 A CN104093405 A CN 104093405A CN 201280051254 A CN201280051254 A CN 201280051254A CN 104093405 A CN104093405 A CN 104093405A
Authority
CN
China
Prior art keywords
extract
therapeutic combination
cisplatin
methods
combination product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280051254.5A
Other languages
English (en)
Chinese (zh)
Inventor
D·R·克诺克
J·B·内斯特
I·帕帕索蒂里欧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerium Biotechnology Inc
Original Assignee
Nerium Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerium Biotechnology Inc filed Critical Nerium Biotechnology Inc
Priority to CN201910226194.XA priority Critical patent/CN110269940A/zh
Publication of CN104093405A publication Critical patent/CN104093405A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201280051254.5A 2011-10-20 2012-10-20 用于治疗癌症的治疗组合 Pending CN104093405A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910226194.XA CN110269940A (zh) 2011-10-20 2012-10-20 用于治疗癌症的治疗组合

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549386P 2011-10-20 2011-10-20
US61/549,386 2011-10-20
PCT/US2012/061226 WO2013059753A1 (en) 2011-10-20 2012-10-20 Therapeutic combination for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910226194.XA Division CN110269940A (zh) 2011-10-20 2012-10-20 用于治疗癌症的治疗组合

Publications (1)

Publication Number Publication Date
CN104093405A true CN104093405A (zh) 2014-10-08

Family

ID=48141445

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280051254.5A Pending CN104093405A (zh) 2011-10-20 2012-10-20 用于治疗癌症的治疗组合
CN201910226194.XA Pending CN110269940A (zh) 2011-10-20 2012-10-20 用于治疗癌症的治疗组合

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910226194.XA Pending CN110269940A (zh) 2011-10-20 2012-10-20 用于治疗癌症的治疗组合

Country Status (13)

Country Link
US (2) US20130209579A1 (enExample)
EP (2) EP2768498B1 (enExample)
JP (1) JP6255346B2 (enExample)
CN (2) CN104093405A (enExample)
AU (3) AU2012325819B2 (enExample)
BR (1) BR112014009421A2 (enExample)
CA (1) CA2852274C (enExample)
GT (1) GT201400071A (enExample)
IL (2) IL231987B (enExample)
IN (1) IN2014KN00796A (enExample)
MX (2) MX365635B (enExample)
RU (2) RU2014120179A (enExample)
WO (1) WO2013059753A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374804B (es) * 2008-10-14 2025-03-06 Nerium Biotechnology Inc Proceso para extraer glucósidos cardíacos y composiciones.
KR102569221B1 (ko) * 2015-04-22 2023-08-21 신-낫 프로덕츠 엔터프라이즈 엘엘씨 공결정 조성물 및 그의 약제학적 용도
JP7038653B2 (ja) * 2015-10-05 2022-03-18 ニューカナ パブリック リミテッド カンパニー 併用療法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060205679A1 (en) * 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
US20070154573A1 (en) * 2005-12-27 2007-07-05 Juay Jamil Rashan Method of preparing and using a cold extract from the leaves of nerium oleander

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC1811A1 (fr) 1986-05-13 1988-03-18 Huseyin Ziya Ozel Extrait de plantes de l'espece nerium procede pour sa preparation et ses applications
CA2354037A1 (en) 1998-09-24 2000-03-30 Ozelle Pharmaceuticals, Inc. Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof
US7407675B2 (en) * 2002-12-27 2008-08-05 The Trustees Of Columbia University In The City Of New York Anti-neoplastic compositions comprising extracts of black cohosh
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
PT2173337E (pt) 2007-08-06 2014-09-03 Univ Ohio Fosfoplatinas e a sua utilização no tratamento de cancros resistentes à cisplantina e carboplatina
MX374804B (es) * 2008-10-14 2025-03-06 Nerium Biotechnology Inc Proceso para extraer glucósidos cardíacos y composiciones.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060205679A1 (en) * 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
US20070154573A1 (en) * 2005-12-27 2007-07-05 Juay Jamil Rashan Method of preparing and using a cold extract from the leaves of nerium oleander

Also Published As

Publication number Publication date
MX2019006685A (es) 2019-08-21
EP2768498B1 (en) 2020-03-04
IL231987B (en) 2020-07-30
US20190343908A1 (en) 2019-11-14
BR112014009421A2 (pt) 2017-04-18
MX365635B (es) 2019-06-10
JP6255346B2 (ja) 2017-12-27
CA2852274C (en) 2019-08-06
EP2768498A4 (en) 2015-06-17
NZ623550A (en) 2016-06-24
AU2019203577A1 (en) 2019-06-13
AU2017254875A1 (en) 2017-11-23
RU2017136415A (ru) 2019-02-08
RU2017136415A3 (enExample) 2021-02-08
IN2014KN00796A (enExample) 2015-10-02
MX2014004527A (es) 2014-09-15
AU2012325819A1 (en) 2014-04-24
WO2013059753A1 (en) 2013-04-25
RU2014120179A (ru) 2015-11-27
CN110269940A (zh) 2019-09-24
EP2768498A1 (en) 2014-08-27
IL231987A0 (en) 2014-05-28
GT201400071A (es) 2015-09-17
CA2852274A1 (en) 2013-04-25
US20130209579A1 (en) 2013-08-15
IL275636A (en) 2020-08-31
JP2014530878A (ja) 2014-11-20
AU2012325819B2 (en) 2017-08-03
EP3711754A1 (en) 2020-09-23

Similar Documents

Publication Publication Date Title
Roh et al. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis
US20250381191A1 (en) Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
KR102056586B1 (ko) Ａｔｒ 억제제를 이용한 췌장암 및 비소세포 폐암의 치료
Qu et al. Astragaloside IV enhances cisplatin chemosensitivity in hepatocellular carcinoma by suppressing MRP2
Kaira et al. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer
Kim et al. A novel herbal medicine, KIOM-C, induces autophagic and apoptotic cell death mediated by activation of JNK and reactive oxygen species in HT1080 human fibrosarcoma cells
Gao et al. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma
US20190343908A1 (en) Therapeutic Combination for the Treatment of Cancer
JP2020530014A (ja) がんを治療するための組み合わせ
Bognar et al. Amiodarone’s major metabolite, desethylamiodarone, induces apoptosis in human cervical cancer cells
Loilome et al. Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma
KR20140032586A (ko) Ｐｔｅｎ 기능저하에 의한 ｅｇｆｒ-ｔｋｉ 저해제-내성 폐암의 방사선 치료용 약학 조성물
CN106389437A (zh) 低剂量西地那非作为抗肿瘤药物的应用
CN103189059A (zh) 治疗耐药性癌症的方法
TW202034919A (zh) 西奧羅尼用於小細胞肺癌的治療
KR20120104594A (ko) 췌장암의 치료 방법
Zhong et al. The therapeutic value of XL388 in human glioma cells
AU2020255063B2 (en) Combined use of A-nor-5α androstane compound drug and anticancer drug
JP6820567B2 (ja) 癌治療剤
Abdulghany Metformin Enhances the Sensitivity of Glioblastoma Cancer Cells to Cisplatin through DNA Damage Assessment
Wu et al. Inhibition of hepatocellular carcinoma progression by artesunate via modulation of the TLR4/MyD88/NF-κB signaling pathway
CN115381954B (zh) 一种用于治疗骨肉瘤的联合用药物
Trédaniel et al. An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients
NZ623550B2 (en) Therapeutic combination for the treatment of cancer
CN103933569A (zh) 一种抗肺癌药物组合物及其应用、药盒和包装件

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20141008

RJ01 Rejection of invention patent application after publication